Navigation Links
Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress
Date:8/25/2009

RIDGEFIELD, Conn., Aug. 25 /PRNewswire/ -- Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).(1)

Atrial fibrillation affects approximately 2.3 million Americans(2) and can increase the risk of stroke five-fold.(3) Top-line findings from the 18,113 patient RE-LY study(1) will be featured in an ESC press briefing on Sunday, Aug. 30 at 8:00 a.m. CEST, with the full results presented in a "Hot-Line" session at 11:00 a.m. CEST. The study will also be simultaneously published in a leading peer-reviewed medical journal.

Dabigatran etexilate is an investigational oral anticoagulant in Phase III development for stroke prevention in AF(1) and several other therapeutic areas, including prevention of atherothrombotic events in patients with acute coronary syndrome,(4) as well as primary prevention, (5),(6),(7) secondary prevention(8) and treatment of venous thromboembolism.(9) Dabigatran etexilate is not yet approved by the U.S. Food and Drug Administration.

In addition to the primary findings, a RE-LY sub-analysis of treatment naive patients will also be presented during a "Clinical Trial Update" session on Wednesday, Sept. 2 at 8:00 a.m. CEST.

About RE-LY: The largest AF outcomes trial to date

RE-LY was a global, Phase III, randomized trial of 18,113 patients(1) enrolled in more than 900 centers in 44 countries,(1) investigating whether dabigatran etexilate (two blinded doses) was as effective as well-con
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
2. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
5. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
6. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
7. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
10. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
11. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... DIEGO , Dec. 17, 2014 Royal ... Volcano Corporation (NASDAQ: VOLC ), a global leader ... announced that they have entered into a definitive merger agreement. ... to acquire all of the issued and outstanding shares of ... purchase price of USD 1 billion (approx. EUR 800 million), ...
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
...  The Society of Pharmaceutical and Biotech Trainers ( SPBT ... of the SPBT Board of Directors, effective January 1, 2012.  ... learning and development, management development, sales, and marketing. ... served as vice president of the SPBT Board since 2006.  ...
... College of Emergency Physicians, a national sponsor of the ... safe disposal of expired, unused and unwanted medications in ... accidental overdose.  A recent study reports that prescription drugs ... 2008, more than half of the total 36,450 overdose ...
Cached Medicine Technology:Carol Wells Elected President of the Society of Pharmaceutical and Biotech Trainers 2Emergency Physicians Tell the Public,''Get Rid of Your Stash'' of Unwanted Meds on November 12th 2
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring wedding ... 1,000 new designs in this collection, and all of ... AngelWeddingDress.com promises to provide the most fashionable ... while many fashion trends come and go. If ladies ... at AngelWeddingDress.com is ready to assist. , “These ...
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, 2014 ... than traditional cigarettes, new research finds. Even though ... thousands of ex-smokers said they have fewer cravings and are ... to smoke, researchers reported. "The pattern was ... use than for tobacco use," said lead researcher Jonathan Foulds, ...
(Date:12/21/2014)... York, NY (PRWEB) December 21, 2014 ... nearing 1,400 in a consolidated litigation underway in New ... documents, a total of 1,375 claims involving the birth ... Superior Court. These lawsuits were filed by women who ... to have led to uterine perforations and other complications ...
(Date:12/21/2014)... Serious Buyer, Andrew Hawley from Vintage ... and the Doors International Ballroom at the Hilton Hotel ... the only time that Morrison's mother would see her ... 1967. According to Hawley, “This would be the Doors ... Alexandria Roller Rink earlier that year and would return ...
(Date:12/21/2014)... Over the past 39 years, NES Health ... emergency departments across the nation, from quality of medical ... into an innovative suite of tools, systems, and programs ... the patient experience. , NES Health, a leading ... services for hospitals, announced the development and launch of ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2
... RONKONKOMA, N.Y., July 10 NBTY, Inc. (NYSE: NTY ... marketer of nutritional supplements, today announced that it will web cast ... NBTY, at the Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure ... The presentation is scheduled to be web cast live on the ...
... Recently, ... during the Anatomy 200 module of their Massage Therapy program at CNI College prepared them ... the main focus in this module. , ... Orange, CA (PRWEB) July 10, 2009 -- Recently, students attended a lab at ...
... ... now a featured expert on searchhearthealth.com, a new informational Web site devoted to all aspects ... Potomac, ... alternative health movement, is now a featured expert on searchhearthealth.com , a new informational ...
... , LA JOLLA, Calif., July 9 TorreyPines Therapeutics, Inc. ... was convened on July 9, 2009, was adjourned to July ... located at 11085 North Torrey Pines Road, Suite 300, La ... to stockholders on or about June 19, 2009, the stockholders ...
... Congressman Chaka Fattah (D-PA), Chairman of the Congressional Urban ... jurisdiction over health policy prepare to introduce legislation on health ... opportunity is at hand for the House of Representatives to ... on all members of the Congressional Urban Caucus to stand ...
... (Nasdaq: CDIC ), the innovator and leader of BioZ(R) ... quarter 2009. Highlights include 11% sequential revenue increase over Q1 ... consecutive quarter of year over year sensor growth. , ... Second Quarter 2008 , , , ...
Cached Medicine News:Health News:NBTY to Webcast Presentation at Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure Conference; Announces Fiscal Third Quarter Preliminary Unaudited Net Sales Results 2Health News:NBTY to Webcast Presentation at Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure Conference; Announces Fiscal Third Quarter Preliminary Unaudited Net Sales Results 3Health News:NBTY to Webcast Presentation at Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure Conference; Announces Fiscal Third Quarter Preliminary Unaudited Net Sales Results 4Health News:CNI College Massage Therapy Students Experience Plastination & Cadaver Lab 2Health News:Dr. Julian Whitaker Featured on Searchhearthealth.com 2Health News:TorreyPines Announces the Adjournment of Its Special Meeting of Stockholders 2Health News:TorreyPines Announces the Adjournment of Its Special Meeting of Stockholders 3Health News:Urban Caucus Chair Urges Caucus Members to 'Get the Job Done' for Health Care Reform 2Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 2Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 3Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 4Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 5
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
Medicine Products: